10-Q: Dominari Holdings Reports Q1 2024 Results, Revenue Growth Offset by Investment Losses

Dominari Holdings saw revenue growth in its financial services segment during Q1 2024, but experienced a net loss due to investment valuation changes.

Summary

• Dominari Holdings reported a net loss of $5.441 million for the quarter ended March 31, 2024, compared to a net loss of $3.762 million for the same period in 2023.
• The company's revenue for the quarter was $1.367 million, primarily driven by commissions and underwriting revenue from its Dominari Securities subsidiary.
• Operating expenses totaled $4.172 million, resulting in a loss from operations of $2.805 million.
• Other expenses, including losses on marketable securities, notes receivable, and long-term equity investments, amounted to $2.636 million.
• The company's cash and cash equivalents decreased to $1.956 million from $2.833 million at the end of 2023.
• Marketable securities decreased from $13.547 million to $5.123 million during the quarter.
• The company is winding down its legacy biotechnology assets and focusing on its financial services business.
• Dominari Securities had net capital of approximately $13.4 million, exceeding the required minimum of $0.1 million.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with revenue growth in the financial services segment, but significant losses due to investment valuations and a material weakness in internal controls. The need for potential capital raises and ongoing legal proceedings further contribute to a negative sentiment.

Positives

• The company generated $1.367 million in revenue, primarily from its financial services segment.
• Dominari Securities is operating with a net capital of $13.4 million, significantly above the required minimum of $0.1 million.
• The company is actively winding down its legacy biotechnology assets to focus on its financial services business.
• The company recognized a gain of approximately $0.6 million on marketable securities for the three months ended March 31, 2024.

Negatives

• The company reported a net loss of $5.441 million for the quarter.
• The company experienced a loss from operations of $2.805 million.
• The company incurred significant losses from changes in the fair value of long-term equity investments, totaling $2.459 million.
• The company recorded a realized loss of approximately $1.0 million on notes receivable.
• Cash and cash equivalents decreased by $877,000 during the quarter.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in internal controls related to the accounting of notes receivable and long-term investments.

Risks

• The company's ongoing administrative and other expenses exceed its non-financing related revenue.
• The company's success is dependent on its ability to generate sufficient cash flow to meet its obligations.
• The company may need to raise additional capital sooner than expected if cash flow from operations is insufficient.
• The company's ability to obtain capital is affected by prevailing conditions in the industry, global economy, and financial markets.
• The company's internal controls over financial reporting have a material weakness.
• The company is facing a legal proceeding related to the hiring of new registered representatives at Dominari Securities.

Future Outlook

The company intends to finance its activities through managing current cash, seeking additional funds through the sale of securities, and exploring credit facilities or other debt arrangements. The company believes its cash and cash equivalents and marketable securities, together with anticipated cash flow from operations, will be sufficient to meet its working capital and capital expenditure requirements for at least the next 12 months.

Management Comments

• The company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC.
• Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets.
• The company is focused on executing its growth strategy in the financial services industry.

Industry Context

The company's transition from biotechnology to financial services reflects a strategic shift to capitalize on opportunities in the fintech and wealth management sectors. The company's acquisition of a broker-dealer and investment advisor aligns with the trend of consolidation and expansion in the financial services industry. The company's performance is impacted by macroeconomic factors such as inflation and global tensions, which are affecting investment valuations across the industry.

Comparison to Industry Standards

• Dominari's revenue of $1.367 million is relatively low compared to larger, established financial services firms such as Charles Schwab (SCHW) or Morgan Stanley (MS), which report billions in quarterly revenue.
• The net loss of $5.441 million is significant, especially when compared to profitable firms in the financial services sector. For example, Interactive Brokers (IBKR) consistently reports net profits.
• Dominari's reliance on investment gains and losses makes its financial results more volatile than firms with more stable fee-based revenue models, such as asset managers like BlackRock (BLK).
• The company's net capital of $13.4 million at Dominari Securities is a positive sign, but it is still small compared to the capital reserves of larger broker-dealers like Goldman Sachs (GS).
• The company's transition from biotechnology to financial services is a significant strategic shift, and its performance will need to be benchmarked against other firms in the financial services industry as it matures.

Legal Proceedings

• In March 2024, the company received a notice of petition of a filed action seeking relief related to the hiring of new registered representatives at Dominari Securities.

Related Party Transactions

• In 2021, the company engaged the services of Revere Securities, LLC, where a board member was previously a director. The company incurred fees of approximately $0 and $80,000 during the three months ending March 31, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and the decrease in asset values.
• Employees in the financial services segment may see growth opportunities, while those in the biotechnology segment may face uncertainty.
• Customers of Dominari Securities may be affected by the company's financial performance and any potential changes in service offerings.
• Creditors may be concerned about the company's ability to meet its obligations given the net loss and potential need for additional capital.

Next Steps

• The company will continue to wind down its legacy biotechnology assets.
• The company will focus on growing its financial services business through Dominari Financial.
• The company will seek partnership opportunities and acquisitions in the financial services industry.
• The company will work to remediate the material weakness in internal controls over financial reporting.

Key Dates

Keywords

financial services, broker-dealer, investment advisory, net loss, revenue, operating expenses, marketable securities, long-term equity investments, internal controls, capital, Dominari Securities, fintech